dostęp otwarty

Tom 2, Nr 3 (2017)
Artykuły oryginalne / Original articles
Opublikowany online: 2017-12-12
Pobierz cytowanie

The tolerance of proton radiotherapy — preliminary results

Beata Sas-Korczyńska1, Elżbieta Pluta, Agnieszka Chrostowska, Dariusz Martynów, Anna Patla, Tomasz Skóra, Dominika Wojton-Dziewońska, Eleonora Góra, Damian Kabat, Kamil Kisielewicz, Tomasz Kajdrowicz, Renata Kopeć
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2017;2(3):207-211.
Afiliacje
  1. Clinic of Oncology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Branch in Gliwice, Poland, Polska

dostęp otwarty

Tom 2, Nr 3 (2017)
Artykuły oryginalne / Original articles
Opublikowany online: 2017-12-12

Streszczenie

Introduction. Because the specific proton beam dose distribution (i.e. the so-called ’Bragg curve’), proton radiotherapy ensures that the high-dose region is precisely confined to the target volume while minimizing the dose delivered to healthy tissues/critical organs surrounding the tumour or to those lying in the path of the proton beam. This method has been used for patients in Kraków since November 2016.

Aim. To report the early tolerance outcomes to proton radiotherapy in patients completing their treatment just before the end of August 2017.

Materials and methods. Study subjects were 47 patients who had completed their treatment before the end of August 2017 with a mean age of 41.6 years (range: 16–76, median: 40). The most frequent diagnoses were skull base tumours (22 pts. — 46.8%) and brain G1 or G2 gliomas (17 pts. — 36.2%), whereas the most frequent histological types were chordomas (17 pts. — 36.2%). Proton radiotherapy was administered by pencil beam scanning and consisted of using the intensity modulated proton therapy (IMPT) technique. The total dose given per cancer type averaged as follows: (i) 70 and 74 Gy(RBE), for respectively chodrosarcomas and chordomas, (ii) 54 Gy(RBE) for brain gliomas and (iii) 70 Gy(RBE) for paranasal sinuses tumours. Early tolerance was prospectively evaluated and measured according to the CTCAE scale, version 4.03.

Results. In all, 91 side effects (SE) were recorded in 44 patients. The intensity of SEs were as following: 62 SEs (68.1%) were of grade 1 intensity, 21 SEs (23.1%) were of grade 2 and 8 SEs (8.8%) were of grade 3. The most frequently developed SEs were skin reactions (29 pts. — 61.7%) or oral/pharyngeal mucositis (20 pts. — 42.6%). Because the patient follow-up period was short, presented results only describes the early tolerance to this therapy. Our findings of mild intensities for the most early side effects, at (grades 1 or 2) are consistent with other published studies.

Streszczenie

Introduction. Because the specific proton beam dose distribution (i.e. the so-called ’Bragg curve’), proton radiotherapy ensures that the high-dose region is precisely confined to the target volume while minimizing the dose delivered to healthy tissues/critical organs surrounding the tumour or to those lying in the path of the proton beam. This method has been used for patients in Kraków since November 2016.

Aim. To report the early tolerance outcomes to proton radiotherapy in patients completing their treatment just before the end of August 2017.

Materials and methods. Study subjects were 47 patients who had completed their treatment before the end of August 2017 with a mean age of 41.6 years (range: 16–76, median: 40). The most frequent diagnoses were skull base tumours (22 pts. — 46.8%) and brain G1 or G2 gliomas (17 pts. — 36.2%), whereas the most frequent histological types were chordomas (17 pts. — 36.2%). Proton radiotherapy was administered by pencil beam scanning and consisted of using the intensity modulated proton therapy (IMPT) technique. The total dose given per cancer type averaged as follows: (i) 70 and 74 Gy(RBE), for respectively chodrosarcomas and chordomas, (ii) 54 Gy(RBE) for brain gliomas and (iii) 70 Gy(RBE) for paranasal sinuses tumours. Early tolerance was prospectively evaluated and measured according to the CTCAE scale, version 4.03.

Results. In all, 91 side effects (SE) were recorded in 44 patients. The intensity of SEs were as following: 62 SEs (68.1%) were of grade 1 intensity, 21 SEs (23.1%) were of grade 2 and 8 SEs (8.8%) were of grade 3. The most frequently developed SEs were skin reactions (29 pts. — 61.7%) or oral/pharyngeal mucositis (20 pts. — 42.6%). Because the patient follow-up period was short, presented results only describes the early tolerance to this therapy. Our findings of mild intensities for the most early side effects, at (grades 1 or 2) are consistent with other published studies.

Pobierz cytowanie

Słowa kluczowe

proton radiotherapy, early tolerance, side effects, pencil beam scanning

Informacje o artykule
Tytuł

The tolerance of proton radiotherapy — preliminary results

Czasopismo

Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory

Numer

Tom 2, Nr 3 (2017)

Strony

207-211

Opublikowany online

2017-12-12

Wyświetlenia strony

319

Wyświetlenia/pobrania artykułu

362

Rekord bibliograficzny

Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2017;2(3):207-211.

Słowa kluczowe

proton radiotherapy
early tolerance
side effects
pencil beam scanning

Autorzy

Beata Sas-Korczyńska
Elżbieta Pluta
Agnieszka Chrostowska
Dariusz Martynów
Anna Patla
Tomasz Skóra
Dominika Wojton-Dziewońska
Eleonora Góra
Damian Kabat
Kamil Kisielewicz
Tomasz Kajdrowicz
Renata Kopeć

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, e-mail: viamedica@viamedica.pl